N Engl J Med. 2008;358:1887 1898. doi: 10.1056/ NEJMoa0801369. 48. Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL Jr, Kaplan NM, O Connor CM, O Gara PT, Oparil S. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention [published correction appears in Circulation. 2007;116:e121]. Circulation. 2007;115:2761 2788. doi: 10.1161/CIRCULATIONAHA. 107.183885. Bozkurt et al 49. Pfeffer MA, Braunwald E, Moy LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins M. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarc- tion. Results of the survival and ventricular enlargement trial: the SAVE Investigators. N Engl J Med. 1992;327:669 677. doi: 10.1056/NEJM199209033271001. 50. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS): the CONSENSUS Trial Study Group. N Engl J Med. 1987;316:1429 1435. 51. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions: the SOLVD Investigators [published correc- tion appears in N Engl J Med. 1992;327:1768]. N Engl J Med. 1992;327:685 691. 52. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treat- ments: a network meta-analysis involving more than 65,000 pa- tients. J Am Coll Cardiol. 2008;52:1769 1781. doi: 10.1016/j. jacc.2008.08.039. 53. Dargie HJ. Effect of carvedilol on outcome after myocardial infarc- tion in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385 1390. 54. 